More than 600,000 people die from Hepatocellular carcinoma (HCC) worldwide annually. The environmental factors that cause HCC are well known and include infection by hepatitis B and C viruses (HBV and HCV), exposure to Aflatoxin B1, and excessive alcohol intake. However, no effective treatments exist for HCC and the prognosis of HCC patients is usually poor, with an overall median survival of less than one year. The RB tumor suppressor and its family member's p107 and p130 are functionally inactivated in nearly all cases of human HCC. This inactivation is due to increased CDK4 kinase activity resulting from the silencing of the CDK4 inhibitor p16 or from increased expression of the CDK4 partner Cyclin D1. In addition, some proteins produced by HBV and HCV can inactivate RB family members, including by triggering their degradation. We generated a mouse model for human HCC by deleting RB family genes in the liver of adult mice to model this functional inactivation of RB family proteins. RB/p107/p130 triple knockout (TKO) mice develop liver tumors whose histology and gene expression profiles resemble human HCCs. The activity of E2F transcription factors, which are normally inhibited by the RB family, is high in TKO HCC cells. TKO HCCs initiate from progenitor cells and not hepatocytes, which do not divide due to unknown mechanisms that suppress their proliferation. The TKO HCC model provides a unique in vivo system to query the mechanisms of tumorigenesis in the liver and to specifically interrogate how RB/E2F transcriptional regulatory complexes control HCC development. Our general hypothesis is that inactivation of the RB pathway drives cancer initiation at least in part by deregulating E2F activity and compromising the balance between regulatory networks in acutely sensitive cell populations. Specifically, we propose that increased E2F activity engages pathways that promote the expansion of mutant cells, including liver progenitors, but also triggers negative feedback loops preventing cancer initiation from mature hepatocytes and limiting the growth of HCC cells. We will first test the specific hypothesis that activation of p21 by E2F in the TKO model blocks the proliferation of hepatocytes, thereby preventing HCC initiation from these mature cells. Next, we will test the idea that activation of Notch signaling y E2F limits the expansion of HCC cells during tumorigenesis. Finally, we will examine the possibility that activation of the EZH2 methyltransferase by E2F promotes the growth of both liver progenitors and HCC cells. To test these hypotheses, we will manipulate the activity of RB and E2F family members, p21 and CDK2, Notch pathway members, and EZH2 in adult liver progenitor cells, mature hepatocytes, and HCC cells in vivo. These experiments in mutant mice will be complemented by analyses of human liver cells ex vivo. Our studies will identify novel means to diagnose, detect, and treat HCC. In addition, because genetic, epigenetic, and/or viral inactivation of the RB pathway is a nearly universal event in human cancer cells, these studies are generally relevant to a broad cross-section of cancer patients.

Public Health Relevance

Hepatocellular carcinoma (HCC) is a malignant tumor of the liver that develops in patients with risk factors such as alcohol abuse, viral hepatitis, and metabolic liver disease;most HCC patients die within one year of diagnosis. Our goal is to develop and study mouse models of HCC associated with loss of function of the RB pathway, a common event in human HCC, to gain a better understanding of the molecular and cellular mechanisms underlying HCC development. We hope that the results of these studies will help identify novel means to diagnose, detect, and treat HCC in patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA114102-07
Application #
8450741
Study Section
Cancer Molecular Pathobiology Study Section (CAMP)
Program Officer
Hildesheim, Jeffrey
Project Start
2006-07-01
Project End
2017-05-31
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
7
Fiscal Year
2013
Total Cost
$261,030
Indirect Cost
$99,018
Name
Stanford University
Department
Pediatrics
Type
Schools of Medicine
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Santos, Mirentxu; Martínez-Fernández, Mónica; Dueñas, Marta et al. (2014) In vivo disruption of an Rb-E2F-Ezh2 signaling loop causes bladder cancer. Cancer Res 74:6565-77
Ntziachristos, Panagiotis; Lim, Jing Shan; Sage, Julien et al. (2014) From fly wings to targeted cancer therapies: a centennial for notch signaling. Cancer Cell 25:318-34
Ehmer, Ursula; Zmoos, Anne-Flore; Auerbach, Raymond K et al. (2014) Organ size control is dominant over Rb family inactivation to restrict proliferation in vivo. Cell Rep 8:371-81
Attardi, Laura D; Sage, Julien (2013) RB goes mitochondrial. Genes Dev 27:975-9
Sage, Julien; Ventura, Andrea (2011) miR than meets the eye. Genes Dev 25:1663-7
Viatour, Patrick; Ehmer, Ursula; Saddic, Louis A et al. (2011) Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway. J Exp Med 208:1963-76
Saddic, Louis A; Wirt, Stacey; Vogel, Hannes et al. (2011) Functional interactions between retinoblastoma and c-MYC in a mouse model of hepatocellular carcinoma. PLoS One 6:e19758
Chen, Hainan; Gu, Xueying; Liu, Yinghua et al. (2011) PDGF signalling controls age-dependent proliferation in pancreatic ?-cells. Nature 478:349-55
McEvoy, Justina; Flores-Otero, Jacqueline; Zhang, Jiakun et al. (2011) Coexpression of normally incompatible developmental pathways in retinoblastoma genesis. Cancer Cell 20:260-75
Teitz, Tal; Stanke, Jennifer J; Federico, Sara et al. (2011) Preclinical models for neuroblastoma: establishing a baseline for treatment. PLoS One 6:e19133

Showing the most recent 10 out of 15 publications